SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : Cymer (CYMI) -- Ignore unavailable to you. Want to Upgrade?


To: Mason Barge who wrote (11536)12/14/1997 10:58:00 PM
From: Shakush  Respond to of 25960
 
Off Topic, sort of, from ft.com

sorry about the formatting.

ft.com

Martin Wolf: Same old IMF medicine

TUESDAY DECEMBER 9 1997

The Fund's prescription for South Korea risks sending the corporate
sector into debt and bankruptcy

Like deer, investors graze happily for a while, ignoring the peril of
predators asleep nearby. Then, when startled, they stampede.
These are the skittish beasts that the International Monetary Fund
is trying to cajole back to their wonted east Asian feeding ground.
The question is whether it is doing this in the best possible way.
The answer is no.

The IMF's mistakes have little to do with the scale of the response. The Fund
and the governments supporting it have mustered a great deal of money to
tackle the crisis that began last June: for Thailand, $17.2bn (œ10.2bn); for
Indonesia, front-line financing of $23bn; and, for South Korea, the $57bn
announced last week. The IMF alone has made $3.9bn available to Thailand,
$10.1bn to Indonesia and $21bn to Korea.

But doing something on a spectacular scale does not make the details right.
There are three precise objections to what the IMF is doing.

The first is that, by imposing a damagingly tough squeeze on economic activity
in affected countries, the IMF risks undermining, not restoring, investor
confidence. The second is that by insisting on faster liberalisation of capital
inflows, the IMF may exacerbate financial vulnerability. The third is that these
vast bailouts may encourage further folly, mainly by lenders.

Careful examination of the Asian crisis reveals why these criticisms have force.
This is a calamity that has befallen the private sector. As Joseph Stiglitz, the
World Bank's chief economist, argued in Kuala Lumpur this month, east Asian
countries suffer neither from fiscal profligacy nor high inflation. Savings are
generally well over 30 per cent of gross domestic product. Both the skills and
work ethic of their peoples are impressive. These are outward-looking
economies whose private sectors have demonstrated global competitiveness.

Thus the comparison between South Korea and the former East Germany
made by David Hale of the Zurich group seems absurd: in 1995 Korea's
exports to competitive world markets were a third of its gross domestic
product. Between 1990 and 1995, export volume grew at an average rate of
7.4 per cent. East Germany had no Samsungs.

If these economies have neither been grossly mismanaged nor failed to
generate internationally competitive production, why have they been subject to
such vicious market attack? The chief answer is that they possess significant
financial weaknesses: credit evaluation is virtually non-existent, corporate
accounts are defective, transactions are influenced by personal relations, and
banks and private companies have inadequate equity.

The salience of these weaknesses has been increased by policy errors, notably
adherence to fixed exchange rates, and turbulence abroad, particularly the
strengthening of the dollar against the yen after April 1995 and the earlier
devaluation of the Chinese yuan. Partial integration into a world financial
system unable to evaluate risk either intelligently or consistently has
exacerbated ill effects. Capital first flowed in on a flood tide, then poured out,
leaving devastation in its wake.

The failure of outsiders to foresee problems ahead has been striking. Two
leading credit rating services, Moody's and Standard & Poor's, failed to
downgrade long-term debt ratings of Indonesia, Malaysia or Thailand in the
year and a half to June 1997. Instead, downgradings followed the crisis - and
exacerbated it.

The IMF's task is to restore confidence and encourage needed reforms. But it
is also to avoid imposing an unnecessarily severe squeeze. This last is not just
the Fund's raison d'ˆtre, but economically essential. If the illness is debt
deflation, a significant economic slowdown must make the patient's condition
worse. High real interest rates in highly indebted economies are dangerous.
For the IMF to treat debt deflation as if it were a traditional ill such as high
inflation and fiscal profligacy is little more scientific than for a doctor to bleed
his patients.

Again, when confronting the challenges of financial liberalisation and reform, a
distinction needs to be made between measures to strengthen the robustness
of the financial sector, on the one hand, and liberalisation of financial
transactions, domestic and foreign, on the other. Partial liberalisation of
transactions within unreformed and undercapitalised financial systems has been
at the root of the crisis. Any such combination is a recipe for disaster.

How well, then, do IMF programmes avoid these dangers? Not particularly
well. Just consider the Korean programme:

short-term interest rates are being raised to over 21 per cent, a real rate
of over 15 per cent;

in spite of a devaluation against the dollar of more than 30 per cent over
the past 12 months, monetary policy is seeking to maintain a low
inflation rate of 5 per cent or less;

the inevitable cyclical loosening of fiscal policy is to be offset by a
structural fiscal tightening of 1« per cent of GDP.

The conclusion: however sick Korean companies and banks may be now,
they will soon be sicker.

Turn then to the structural reforms in Korea. Foreign investment in domestic
financial institutions is to be liberalised, as is foreign equity investment. These
are helpful changes. But the decision to open domestic money and bond
markets to foreign investors is highly questionable in current circumstances. As
for proposed elimination of restrictions on foreign borrowings by domestic
corporations, this looks dangerous. The last thing one gives quite-possibly
bankrupt companies is freedom to borrow themselves out of trouble.

These weaknesses are significant enough. Unhappily, there is more. The IMF
may have halted the contagion and could, if its programme works, help restore
the confidence needed for new lending and investment. But it has also helped
bail out foolish investors.

A study from the Washington-based Institute for International Finance,
released last week, shows just how over-optimistic lenders to emerging
markets became between the second quarter of 1995 and the third quarter of
this year.* The risk is that they may return to their old ways too soon.

To be fair to the IMF, there are no easy ways out of a financial crisis, once
started. There is always a trade-off between dealing with the panic, initiating
fundamental reforms and minimising moral hazard.

For this reason, it is even more important to prevent crises in the first place.
For developing countries, the lessons of this one include avoiding exchange
rate pegs, strengthening financial systems and creating effective ways to
restructure company finances. East Asian governments, ever pragmatic, are
likely to learn these lessons swiftly.

Yet lessons do not stop with countries caught out this time. The global
financial system seems vulnerable to manic swings of mood. The
powers-that-be need to ask why crises arise so often and what they can do to
prevent them. The big task is not just to halt the present panic. It is to minimise
the chances of recurrence. But that is a subject for another column.

William Cline and Kevin Barnes, Spreads and Risks in Emerging
Market Lending, Washington, Institute for International Finance,
December 1997.



To: Mason Barge who wrote (11536)12/14/1997 11:10:00 PM
From: John Chalker  Read Replies (1) | Respond to of 25960
 
Mason, Whoa, I'd like to discuss some of your points further. All is well until I get to #5. and your reference to DUV's life. There is no statement that I have seen anywhere which indicates that ANY alternative to DUV could come on line with a production model any sooner than 2003. IBM is just constructing a pilot/demo plant now to prove X Ray litho, no way will a production machine be ready in two years. The Japanese have been unable to make any headway there. Lucent wants 10 partners to help with E beam technology. None of this even addresses issues like throughput rates or clean room footprints. These are all good FUTURE alternatives but no chip manufacturer is going to wait even 3 years for an alternative to DUV. Look at what's happening with DRAMs. A 16 MB DRAM sells for under $3, that's less than the cost of manufacture. To be competitive and profitable, you need the efficiencies of producing a 16 MB DRAM, which sells for $15. You need new tools, like DUV, to produce that product. If you don't keep up, you must fall out of the race, ala bankruptcy.

A consultant once told me that this business is about Economics first, Marketing second, and Technology third. If you can't afford to build the modern fab today, your competition will. And then you will lose market share waiting for E beam or XRL. In short, its like poker with no betting limit. You got to pay to play.

Chalks



To: Mason Barge who wrote (11536)12/14/1997 11:40:00 PM
From: TideGlider  Respond to of 25960
 
Mason: Please name verifiable sources of your statements.
Especially #1 and #2.

Bruce



To: Mason Barge who wrote (11536)12/14/1997 11:49:00 PM
From: FJB  Read Replies (3) | Respond to of 25960
 
Hi Mason,

I'll take the opposite side for the points you've presented.

1. An apparent lack of candor from management at Cymer and several stepper fabs about possible downsides, use of Komatsu lasers, and equipment failures/problems. They've lost a lot of faith.

Cymer has claimed 80% to 90% market share for DUV lasers. This, by definition, means that other lasers companies do in fact ship lasers into this market. The only point on which I can question management is after a conversation with a high-level Nikon executive, the Nikon person told Cymer that they had not shipped any steppers with a non-Cymer source. Clearly, Cymer was lied to on this point, if the other reports about Nikon are true.

As far as "problems" go, there is most likely widespread confusion between "problems" and maintenance. They published a report which states which subsystems require maintenance and on what intervals. I assume these maintenance issues were the primary concerns of the continuous improvement program implemented by Cymer last quarter.
cymer.com
Message 2892100
Message 2892971

They've lost a lot of faith.
I'm not sure what this means.

2. Inability of stepper manufacturers to manufacture steppers ("steppers" meaning all DUV photolith, including step-and-scan) as fast as announced, because of technical problems.

Cymer has mentioned on several occasions that making these tools is difficult. Common sense would also tell us this, but I'm pretty sure the learning curve applies to the manufacture of DUV tools, so this will work itself out. The difficulty in manufacturing DUV tools is the primary reason that demand for the tools outstrips supply at this point.

3. Increasing possibility of future push-outs of stepper orders in Asia due to inability to get financing.

There will most likely be some pushouts from Korean manufacturers because of the financing concerns. Fortunately for Cymer, there is a large imbalance in the supply/demand for DUV tools with demand exceeding supply. Korea represents less than 10% of the capital equipment market. Should Korea be unable to finance technology upgrades(DUV), there are US, European, and Taiwanese firms that can fill the gap.
Message 2920496
Message 2957945

4. Increasing competition from Komatsu, and as time goes by, increasing possibility of competition from Coherent.

Cymer expects competition. Goto said Komatsu will be able to manufacture 21 lasers Jan. to Mar. '98 which would mean current market shares will at least hold true through this time period. Also, it will be interesting to see how competition responds to Cymer's pulse-stretched and multi-KHz technology initiatives. Should Cymer ship such lasers in a timely fashion, everyone will have to reevaluate their commitment to second sources whose products have been obsoleted.

5. Uncertainty about the effective life of DUV technology (such as IBM's x-ray fab).

There is very little uncertainty about the life expectancy and advantages of DUV. There is much uncertainty about whether, EUV, X-ray, or E-beam will be the replacement technology.
techweb.cmp.com
techweb.cmp.com
Message 2847812

Questions, comments, flames?

Bob



To: Mason Barge who wrote (11536)12/15/1997 1:02:00 AM
From: Gemini  Respond to of 25960
 
Didn't Cymer announce recently that it was hiring a PR firm to
takeover many of the investor relation functions?

The continuing silence from headquarters can result in bearish
consequences. Hello "A-Team", is anyone home????

A Cymer long, Allan